This application requests renewal for years 29-33 of the NCI Cancer Center Support Grant (CCSG) for the Barbara Ann Karmanos Cancer Institute (KCI) at Wayne State University. The Programs of KCI reflect the cancer needs of the greater Metropolitan Detroit area. This is an industrialized, urban and ethnically diverse community with a disproportionate number of medically disadvantaged, low socio-economic citizens. KCI has a long-standing and extensive commitment to both research and clinical services that address the prevention, early detection and treatment of cancer, particularly of African Americans who carry a disproportionate cancer burden. This application requests support for five Programs, ten Cores, Developmental Funds, five Staff Investigators, and related administrative support. KCI's established Programs are Breast Cancer Biology;Developmental Therapeutics;Molecular Biology and Genetics;Population Studies and Disparities Research, and Proteases and Cancer. Our Programs are organized to integrate basic, translational, and clinical research with population research-based cancer control activities. Additionally, CCSG support is requested for ten Cores, in Behavioral and Field Research;Biorepository;Epidemiology Research;Genomics;Microscopy, Imaging and Cytometry Resources;Pharmacology;Proteomics;Systems and Computational Biology;Biostatistics;and Clinical Trials Office. KCI fosters inter-disciplinary interactions and collaborations, utilizes CCSG Developmental Funds to recruit new investigators, encourages translational research Programs, and develops new Shared Resources (Cores) to support KCI members. Research growth continues, as demonstrated by increases in the number of publications and the recruitment of internationally recognized scientists. KCI has 235 members, 170 are Scientific Members and 65 are Clinical Members representing 40 departments and institutes from Wayne State University, Henry Ford Health System, University of Windsor, and Michigan State University. KCI's total annual direct grant funding is $63,296,703 of which $42,441,739 is peer reviewed funding. Of the peer reviewed funding, 6 1 % is from NCI. Over the last grant period, members'published 2,980 papers, 38% and 35% were intra- and inter-programmatic, respectively and 24% were both intra- and inter-programmatic.

Public Health Relevance

Cancer is the second leading cause of mortality in the United States and disproportionately affects minorities. It is through the clinical, basic, population and translational research conducted at KCI that we can make strides towards reducing mortality and morbidity associated with cancer, with a continued commitment to address the disproportionate cancer burden among minorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-31S1
Application #
8709335
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-08-08
Project End
2015-11-30
Budget Start
2013-09-30
Budget End
2013-11-30
Support Year
31
Fiscal Year
2013
Total Cost
$12,500
Indirect Cost
$4,276
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597
Cheriyan, Vino T; Alsaab, Hashem; Sekhar, Sreeja et al. (2018) A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget 9:29680-29697
Burl, Rayanne B; Ramseyer, Vanesa D; Rondini, Elizabeth A et al. (2018) Deconstructing Adipogenesis Induced by ?3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab 28:300-309.e4
Dedigama-Arachchige, Pavithra M; Acharige, Nuwan P N; Pflum, Mary Kay H (2018) Identification of PP1-Gadd34 substrates involved in the unfolded protein response using K-BIPS, a method for phosphatase substrate identification. Mol Omics 14:121-133

Showing the most recent 10 out of 826 publications